“The problem is not that there isn't enough drug company money available for CME. The problem is that there's so much that it's distorting the entire system.” That was the pro-vocative comment made by Richard Van Harrison, PhD, CME director at the University of Michigan Medical School, when we interviewed him for an article on alternative sources for CME (see page 22). Intrigued, we asked Harrison, who also is a member of the National Task Force on CME Provider/Industry Collaboration, and ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only gain access to Printer-friendly, you'll get exclusive access to a large archive of premium content.

Already registered? here.